Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Intraocular Pressure After 2 Hours of Small-Diameter Scleral Lens Wear

Nau, Cherie B. O.D.; Schornack, Muriel M. O.D.; McLaren, Jay W. Ph.D.; Sit, Arthur J. S.M., M.D.

Eye & Contact Lens: Science & Clinical Practice: November 2016 - Volume 42 - Issue 6 - p 350–353
doi: 10.1097/ICL.0000000000000214
Article
Buy

Objectives: Compression of episcleral veins or deformation of tissue in the Schlemm's canal beneath the landing zone of scleral lenses could elevate intraocular pressure (IOP). We examined the effect of 2 hr of small-diameter scleral lens wear on IOP.

Methods: Twenty-nine participants, 29 ± 6 years old (mean ± SD) who experienced no history of eye disease or scleral lens wear, were included in the study. Each participant was fitted with a 15-mm Jupiter scleral lens on one eye (study eye). Intraocular pressure was measured in both eyes by pneumatonometry centrally on the cornea and peripherally on the sclera. The lens was then placed on one eye and was worn for 2 hr. Intraocular pressure was remeasured immediately after lens placement, at 1 and 2 hr of lens wear, and immediately after lens removal. Intraocular pressure after removal of the scleral lens was compared with IOP before placing the lens and to IOP in the control eye using paired t tests.

Results: Immediately after removing the scleral lens, mean central IOP in the study eye (13.9 ± 3.1 mm Hg) was not different from mean central IOP in the control eye (13.5 ± 2.2 mm Hg, P = 0.4) or in the same eye before lens wear (13.6 ± 1.9 mm Hg, P = 0.6). There were also no differences in IOP measured peripherally at 2 hr of lens wear (P = 0.8).

Conclusions: Neophyte scleral lens wear of a 15-mm scleral lens for 2 hr does not increase IOP in healthy eyes.

Department of Ophthalmology, Mayo Clinic, Rochester, MN.

Address correspondence to Cherie B. Nau, O.D., Department of Ophthalmology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: nau.cherie@mayo.edu

Funding from Research to Prevent Blindness and UL1 TR000135. A. J. Sit. is a consultant for AcuMEMS, Inc.; Allergan, Inc.; and Sensimed AG. A. J. Sit. has a financial interest in Aerie Pharmaceuticals, Inc., and Glaukos Corp.

The authors have no other conflicts of interest to disclose.

Supported by the Mayo Clinic CTSA through grant number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH).

Presented in part at the Association for Research in Vision and Ophthalmology Annual Meeting, May 7, 2014, Orlando, FL.

Accepted September 28, 2015

© 2016 Contact Lens Association of Ophthalmologists, Inc.